Atebrioz (Zilurgisertib): A New Targeted Treatment for Fibrodysplasia Ossificans Progressiva
Atebrioz, whose active ingredient is zilurgisertib, is a newly approved oral medication for fibrodysplasia ossificans progressiva (FOP), an extremely rare genetic disorder in which bone progressively forms in tissues where bone normally should not develop. On September 25, 2026, the U.S. Food and Drug Administration (FDA) approved Atebrioz to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with FOP (U.S. Food and Drug Administration [FDA], 2026a).
Atebrioz is significant because it targets a molecular pathway directly involved in abnormal bone formation. Zilurgisertib is an oral inhibitor of activin receptor-like kinase 2 (ALK2), which is encoded by the ACVR1 gene. In FOP, disease-causing ACVR1 mutations result in abnormal signaling that promotes inappropriate bone formation. By inhibiting ALK2, zilurgisertib is designed to reduce the development of new heterotopic bone rather than merely treating the consequences after abnormal bone has formed (FDA, 2026a; Nguyen et al., 2025).
What Is Fibrodysplasia Ossificans Progressiva?
Fibrodysplasia ossificans progressiva is a rare inherited disorder characterized by progressive formation of bone within soft tissues. Muscles, tendons, ligaments, and other connective tissues can gradually become ossified, resulting in a process known as heterotopic ossification (HO). As additional bone develops, joints and other structures can become increasingly restricted, leading to substantial loss of movement and physical function (FDA, 2026a).
FOP is generally caused by an activating mutation in the ACVR1 gene. ACVR1 encodes ALK2, a receptor involved in bone morphogenetic protein signaling. In affected individuals, abnormal activation of this pathway promotes inappropriate bone formation after physical injury, inflammation, or other triggers. The disease is inherited in an autosomal-dominant manner, although most cases arise from a new mutation rather than being inherited from an affected parent (Nguyen et al., 2025).
FOP usually becomes apparent during childhood. People may experience painful episodes of swelling and inflammation, followed by the development of additional heterotopic bone. Repeated episodes can gradually restrict movement and cause permanent disability. Because FOP is extremely rare and can initially resemble other conditions, accurate diagnosis and specialized care are important.
What Is Heterotopic Ossification?
Heterotopic ossification refers to the formation of mature bone outside the normal skeletal system. In FOP, this abnormal bone may develop within muscles, tendons, ligaments, fascia, and other soft tissues. Unlike temporary swelling or scar tissue, heterotopic bone can become structurally organized and permanently restrict movement.
Abnormal bone around the shoulders, hips, elbows, knees, jaw, or spine can interfere with walking, eating, reaching, personal care, and other everyday activities. In advanced disease, involvement of the chest wall can also restrict expansion of the rib cage and affect respiratory function (FDA, 2026a).
An important characteristic of FOP is that tissue trauma can trigger disease activity. Certain invasive procedures, including intramuscular injections, biopsies, and some surgical procedures, may provoke flare-ups and additional bone formation. This makes specialized management particularly important for people with known or suspected FOP.
How Does Atebrioz Work?
Atebrioz contains zilurgisertib, a selective small-molecule inhibitor of ALK2. ALK2 is part of the bone morphogenetic protein signaling system that regulates bone formation. In FOP, mutations affecting ACVR1 cause abnormal activation of this pathway.
Zilurgisertib inhibits ALK2 kinase activity, thereby reducing signaling that contributes to abnormal heterotopic bone formation. Preclinical research found that zilurgisertib suppressed heterotopic ossification in experimental FOP models and demonstrated high selectivity for ALK2 compared with other related signaling receptors (Nguyen et al., 2025).
This mechanism represents a form of targeted or precision therapy. Rather than addressing only pain or inflammation, the medication attempts to interfere directly with a disease-driving pathway. Such targeted approaches are increasingly important in rare genetic disorders where conventional treatments may not adequately modify disease progression.
Atebrioz Does Not Remove Existing Abnormal Bone
An important distinction is that Atebrioz is intended to reduce the formation of new heterotopic ossification. It is not a medication that dissolves or removes bone that has already developed.
Existing heterotopic bone can substantially restrict movement. However, surgical removal may be problematic because tissue trauma can stimulate additional FOP activity and lead to more abnormal bone formation. Consequently, preventing or reducing new bone formation is a central therapeutic goal in FOP (FDA, 2026a).
This distinction is important for patients and families because treatment success should not necessarily be judged by whether existing abnormal bone disappears. The FDA approval is specifically based on reducing the volume of new heterotopic ossification.
FDA Approval of Atebrioz
The FDA approved Atebrioz on September 25, 2026, making it the third FDA-approved treatment for FOP. Its approved indication is to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with FOP (FDA, 2026a).
The recommended starting dose is 100 mg taken orally once daily, with or without food. The FDA approval letter confirms that the indication applies to adults and pediatric patients aged 12 years and older.
The treatment received Fast Track and Priority Review designations as well as Orphan Drug designation during its development, reflecting the seriousness and rarity of FOP and the limited number of available disease-modifying treatments (FDA, 2026a).
Evidence From the PROGRESS Clinical Trial
The approval of Atebrioz was supported by the PROGRESS study, a randomized, double-blind, placebo-controlled clinical trial. The pivotal study included 63 patients with FOP, who were randomly assigned to receive either zilurgisertib 100 mg once daily or placebo for 24 weeks. Participants could then enter a longer open-label extension in which they received zilurgisertib (FDA, 2026a).
The principal efficacy measure was the change from baseline in the volume of total new heterotopic ossification, assessed using whole-body computed tomography. At week 24, the group receiving zilurgisertib had an average 3.2 cm³ decrease in total new heterotopic ossification volume, while the placebo group had an average 24.6 cm³ increase (FDA, 2026a).
These results provide controlled evidence that ALK2 inhibition can reduce the development or expansion of new abnormal bone in FOP. Longer-term follow-up is important, however, because FOP is a lifelong progressive condition and the clinical value of reducing new bone formation must be evaluated over many years.
What the Trial Means Clinically
The clinical significance of the PROGRESS results lies in the fact that the trial compared zilurgisertib directly with placebo under randomized conditions. The difference in new heterotopic ossification volume suggests that the medication modifies an important biological feature of FOP rather than merely improving subjective symptoms.
At the same time, the trial was necessarily small because FOP is exceptionally rare. A sample of 63 participants provides meaningful evidence but is much smaller than studies used to evaluate medications for common diseases. Continued post-approval monitoring and long-term research will therefore remain important for understanding safety, durability of treatment response, and effects on important outcomes such as mobility and quality of life.
Potential Benefits of Atebrioz
The principal potential benefit of Atebrioz is reduction in the amount of new abnormal bone that develops over time. Because each new episode of heterotopic ossification can contribute to permanent loss of movement, slowing this process may help preserve physical function for longer.
Reducing abnormal bone formation may also decrease the cumulative burden of complications associated with progressive FOP. However, the FDA's approval does not establish that Atebrioz cures FOP or reverses existing disability. Its demonstrated benefit is reduction in the volume of total new heterotopic ossification (FDA, 2026a).
Further research will be needed to determine how reductions in CT-measured bone volume translate into long-term outcomes involving mobility, independence, respiratory function, and overall quality of life.
Common Side Effects
Atebrioz can cause adverse reactions. According to the FDA, the most common side effects reported with treatment include headache, joint pain, upper respiratory tract infection, nosebleeds, and nausea (FDA, 2026a).
Clinical trial reports indicated that most adverse events during the placebo-controlled period were mild or moderate. The safety profile observed in the pivotal study included FOP flare-ups or FOP-related pain, headache, upper respiratory infections, arthralgia, epistaxis, and nausea (Mirum Pharmaceuticals & Incyte, 2026).
Patients should nevertheless report concerning or persistent symptoms to their healthcare professionals. Because the drug is intended for long-term management of a rare progressive disorder, ongoing safety monitoring will be an important component of treatment.
Pregnancy and Reproductive Considerations
Pregnancy is an important safety consideration with Atebrioz. The FDA states that zilurgisertib may cause fetal harm based on animal data. People who can become pregnant should use effective contraception while receiving treatment, and the FDA advises patients to discontinue the medication and contact their healthcare provider if pregnancy occurs (FDA, 2026a).
Because human pregnancy data are limited, treatment decisions involving pregnancy require individualized medical assessment. Patients should discuss pregnancy plans with their healthcare professionals before beginning therapy.
Drug Interactions
Medication interactions are another important consideration. Current prescribing information includes restrictions involving certain medications that can alter zilurgisertib exposure. In particular, drugs that strongly inhibit or induce CYP3A4 can affect zilurgisertib concentrations, and coadministration with certain medications, including metformin, requires special attention under the prescribing information (FDA, 2026a).
Patients should provide their healthcare professionals with a complete list of prescription medicines, over-the-counter products, vitamins, and herbal supplements before starting Atebrioz. Medication changes should be made only under professional guidance because interactions may alter treatment effectiveness or increase the risk of adverse effects.
Atebrioz and Other FOP Treatments
Atebrioz is now part of an expanding group of treatments for FOP. Palovarotene, approved in 2023, was the first FDA-approved therapy for the disease. In August 2026, the FDA approved garetosmab (Pasatru) as a second treatment for adults with FOP. Atebrioz became the third U.S.-approved treatment in September 2026 (FDA, 2026a, 2026b).
These therapies have different mechanisms and approved populations. Zilurgisertib directly inhibits ALK2 signaling, while other therapies target different pathways involved in heterotopic ossification. The availability of several treatment approaches may expand the ability of specialists to individualize care.
However, the existence of multiple treatments does not mean that they are interchangeable. Their eligibility requirements, dosing schedules, safety profiles, and supporting evidence differ. Treatment decisions should therefore be individualized by clinicians familiar with FOP.
Why Specialized Care Matters
FOP requires specialized medical management because procedures that cause tissue injury may provoke disease activity. Healthcare professionals caring for someone with FOP need to consider the potential consequences of intramuscular injections, biopsies, surgery, and other interventions that might be routine in other patients.
Once FOP has been diagnosed, patients and families can benefit from education about avoiding unnecessary trauma, recognizing flare-ups, and coordinating care among specialists. Genetic counseling may also be appropriate because FOP results from a pathogenic ACVR1 variant and follows an autosomal-dominant inheritance pattern.
A multidisciplinary approach may involve genetics, orthopedics, rehabilitation medicine, respiratory care, pain management, nutrition, and other specialties depending on the individual's needs.
Rehabilitation and Supportive Care
Although Atebrioz targets the molecular pathway involved in abnormal bone formation, medication is only one part of comprehensive FOP management. Rehabilitation, mobility assistance, occupational therapy, nutritional support, respiratory monitoring, and appropriate pain management may remain necessary.
Physical therapy should be individualized and performed by professionals familiar with FOP because excessive force or unnecessary trauma can potentially trigger new disease activity. The goal is generally to preserve safe functional ability while minimizing injury.
Emotional and social support are also important. Progressive loss of movement can affect employment, education, relationships, independence, and family responsibilities. Psychological and social support can therefore complement medical treatment and help patients and caregivers adapt to a chronic rare disease.
The Future of FOP Treatment
The development of Atebrioz illustrates how understanding the genetic and molecular basis of rare diseases can lead to targeted treatment. Instead of treating only the consequences of abnormal bone formation, zilurgisertib targets ALK2, a central component of the pathway disrupted by FOP-associated ACVR1 mutations.
The PROGRESS findings provide evidence that ALK2 inhibition can reduce new heterotopic ossification in people with FOP. Nevertheless, several questions remain. Researchers will need to determine the long-term durability of the effect, the impact on mobility and quality of life, optimal treatment duration, and the role of treatment in younger patients.
Further research may also establish whether starting treatment earlier in the disease course can preserve more function. These questions are particularly important because FOP begins early and accumulates irreversible skeletal changes over time.
Conclusion
Atebrioz (zilurgisertib) represents an important development in the treatment of fibrodysplasia ossificans progressiva, an extremely rare genetic disease characterized by progressive abnormal bone formation in soft tissues. Approved by the FDA on September 25, 2026, Atebrioz is indicated for adults and pediatric patients aged 12 years and older to reduce the volume of total new heterotopic ossification (FDA, 2026a).
The medication works by inhibiting ALK2, a signaling receptor affected by disease-causing ACVR1 mutations. In the pivotal PROGRESS study, patients receiving 100 mg of zilurgisertib daily experienced an average 3.2 cm³ decrease in total new heterotopic ossification volume at 24 weeks, compared with a 24.6 cm³ increase among patients receiving placebo (FDA, 2026a).
Atebrioz is not a cure and does not remove abnormal bone that has already formed. Its demonstrated role is to reduce new heterotopic ossification. Long-term studies will be important for determining whether this reduction translates into meaningful preservation of mobility, independence, respiratory function, and quality of life.
For people living with FOP and their families, the availability of another targeted treatment expands the medical options for managing this rare and progressive disease. Continued research, specialized care, rehabilitation, careful monitoring, and patient education will remain important as clinicians and researchers work to improve long-term outcomes.
References
FDA. (2026a, September 25). FDA approves third treatment for fibrodysplasia ossificans progressiva. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
FDA. (2026b, August 19). FDA approves second treatment for fibrodysplasia ossificans progressiva. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva
International Fibrodysplasia Ossificans Progressiva Association. (2026). PROGRESS trial: Zilurgisertib.
Mirum Pharmaceuticals, Inc., & Incyte. (2026, June 14). Mirum Pharmaceuticals and Incyte announce positive pivotal Phase 2 results from PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva.
Nguyen, T. V., et al. (2025). Discovery and characterization of zilurgisertib, a potent and selective inhibitor of activin receptor-like kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva. ACS Omega. https://pubmed.ncbi.nlm.nih.gov/41256990/
Yang, Y.-O., Yang, H., Liu, X., Gong, X., Getsy, J., & Rockich, K. (2026). Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor-like kinase-2 (ALK2) inhibitor, in healthy participants. Clinical Pharmacology in Drug Development, 15(2), e1618. https://doi.org/10.1002/cpdd.1618
Comments